


or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.

[0010d] In another aspect, there is provided use of a compound in the manufacture of a medicament for improvement of the modified Rodnan skin score, reduction or improvement of the skin thickness, reduction or improvement of skin induration, improvement of the pulmonary function, improvement of the dermatology quality of life index, improvement of the carbon monoxide diffusing capacity, improvement of the Mahler Dyspnea index, improvement of the Saint George's Respiratory Questionnaire score, improvement of the UCLA scleroderma clinical trial consortium gastrointestinal tract score, improvement of flow-mediated dilatation or improvement or increase of the six minute walk distance of a patient having scleroderma, wherein the compound is a compound of formula I:



or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.

~~[0010e] In another aspect, there is provided use of a compound for the manufacture of a medicament for modulating activity of a B cell, wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt, solid form, solvate, hydrate, tautomer, stereoisomer or racemate thereof.~~

~~[0010f] In another aspect, there is provided use of a compound for the manufacture of a medicament for modulating activity of a T cell, wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt, solid form, solvate, hydrate, tautomer, stereoisomer or racemate thereof.~~

17. The use of any one of claims 1-16, wherein the medicament is to be administered in combination with a second active agent, which is an anti-inflammatory or immunomodulatory compound.

18. The use of any one of claims 1-17, wherein the effective amount of the compound I is about 0.005 mg/kg to about 10 mg/kg of the patient's body weight.

~~19. Use of a compound for the manufacture of a medicament for modulating activity of a B cell, wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt, solid form, solvate, hydrate, tautomer, stereoisomer or racemate thereof.~~

~~20. Use of a compound for the manufacture of a medicament for modulating activity of a T cell, wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt, solid form, solvate, hydrate, tautomer, stereoisomer or racemate thereof.~~